

ANTIGENICS INC /DE/  
Form 4  
February 12, 2008

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
KLASKIN CHRISTINE M

(Last) (First) (Middle)

162 FIFTH AVE., SUITE 900

(Street)

NEW YORK, NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
ANTIGENICS INC /DE/ [AGEN]

3. Date of Earliest Transaction (Month/Day/Year)  
01/05/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
VP, Finance

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock	01/07/2008		A <sup>(3)</sup>	4,336 A ③	6,914	D	
Common Stock	01/07/2008		F <sup>(4)</sup>	1,845 A \$ 2.15	5,069	D	
Common Stock	03/22/2007		A <sup>(8)</sup>	500 A ⑧	2,791	D	
Common Stock	03/22/2007		F <sup>(4)</sup>	213 A \$ 1.97	2,578	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)	Amount or Number of Shares
Restricted Stock	<u>(5)</u>	01/05/2007		A	8,672	01/05/2008 <sup>(1)</sup> 01/05/2009	Common Stock	8,672
Stock Option, right to buy	\$ 2.27	09/12/2007		A	48,900	09/12/2008 <sup>(2)</sup> 09/12/2017	Common Stock	48,900
Restricted Stock	<u>(5)</u>	01/10/2008		A	15,148	07/10/2008 <sup>(6)</sup> <sup>(6)</sup>	Common Stock	15,148
Restricted Stock	<u>(5)</u>	01/10/2008		A	15,147	01/10/2009 <sup>(7)</sup> <sup>(7)</sup>	Common Stock	15,147

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KLASKIN CHRISTINE M 162 FIFTH AVE. SUITE 900 NEW YORK, NY 10010			VP, Finance	

## Signatures

Christine M. Klaskin  
02/12/2008  
Date

\*\*Signature of Reporting Person

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Restricted Stock granted in accordance with the Antigenics Inc. 1999 Equity Incentive Plan, as amended, and vests equally over two years beginning January 5, 2008.
- (2) Options vest in four equal annual installments beginning September 12, 2008.
- (3) Represents settlement of vested restricted shares granted on January 5, 2007.
- (4) Represents exclusively, shares withheld by Antigenics Inc. in respect of payment of the withholding tax liability upon the vesting of restricted shares.
- (5) Restricted Stock granted in accordance with the terms of the Antigenics Inc. 1999 Equity Incentive Plan, as amended.
- (6) Vests on July 10, 2008.
- (7) Vests on July 10, 2009.
- (8) Represents settlement of restricted shares granted on March 22, 2006.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.